GO:1901800 positive regulation of proteasomal protein catabolic process: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901800 describes any process that activates or increases the frequency, rate or extent of proteasomal protein catabolic process.
• Positive regulation of proteasomal protein catabolic process is essential for protein quality control, cell cycle progression, apoptosis, and immune responses.
• Key regulators include ubiquitin ligases such as KLHL6 and FBXO5, which target substrates for proteasomal degradation.
• Dysregulation of this process contributes to cancer, neurodegeneration, and T cell exhaustion.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of proteasome regulatory genes.
• Proteasome-guided signalling and extracellular proteasome biology are emerging areas with therapeutic implications.
Description
The ubiquitin-proteasome system (UPS) is the major pathway for selective protein degradation in eukaryotic cells, controlling the turnover of short-lived regulatory proteins and misfolded proteins. The Gene Ontology term GO:1901800, positive regulation of proteasomal protein catabolic process, captures any molecular event that enhances the activity or efficiency of this degradation machinery. This term is critical because proteasomal degradation is not merely a housekeeping function; it is a highly regulated process that determines cell fate, immune surveillance, and responses to stress. Understanding how this process is positively regulated provides mechanistic insights into diseases ranging from cancer to neurodegeneration. Recent studies have identified ubiquitin ligases, such as KLHL6 and FBXO5, that drive substrate recognition and proteasomal degradation, thereby influencing T cell dysfunction and chemoresistance. Moreover, proteasome-guided haem signalling has been linked to T cell exhaustion, highlighting the broad physiological impact of this regulatory process. This article synthesizes current knowledge on GO:1901800, covering its definition, mechanisms, key genes, disease relevance, and experimental models for research.
positive regulation of proteasomal protein catabolic process At A Glance
| GO ID | GO:1901800 |
|---|---|
| GO term | positive regulation of proteasomal protein catabolic process |
| Ontology | biological_process |
| Synonym | activation of proteasomal protein catabolic process; upregulation of proteasome-mediated protein catabolism |
| Major function | Enhances the degradation of proteins by the proteasome, impacting cell cycle, apoptosis, and immune responses |
| Related processes | Ubiquitination, proteasome assembly, substrate recognition |
| Disease relevance | Cancer, neurodegeneration, T cell exhaustion, chemoresistance |
| Research tools | CRISPR KO, point mutation, knock-in, overexpression, proteomics |
What Is GO:1901800?
GO:1901800 is defined as any process that activates or increases the frequency, rate or extent of proteasomal protein catabolic process. In other words, it encompasses molecular events that upregulate the degradation of proteins by the proteasome, including the activation of ubiquitin ligases, enhancement of proteasome activity, or facilitation of substrate delivery to the proteasome.
Why Is positive regulation of proteasomal protein catabolic process Important in Cell Biology?
Positive regulation of proteasomal protein catabolic process is fundamental to cellular homeostasis because it controls the timely destruction of regulatory proteins, such as cell cycle inhibitors, transcription factors, and misfolded proteins. Dysregulation of this process can lead to uncontrolled cell proliferation, impaired immune responses, or accumulation of toxic protein aggregates. For researchers, understanding the positive regulators of proteasomal degradation offers opportunities to develop targeted therapies for cancer, neurodegenerative diseases, and immune disorders.
• Controls cell cycle progression by degrading cyclins and CDK inhibitors.
• Regulates apoptosis through degradation of pro- and anti-apoptotic factors.
• Modulates immune responses by targeting signalling proteins in T cells.
• Contributes to chemoresistance in cancers such as glioblastoma and bladder cancer.
• Involved in protein quality control and prevention of neurodegeneration.
• Affects metabolic reprogramming in cancer cells.
• Regulates extracellular proteasome function and intercellular communication.
• Plays a role in fission yeast petite-negativity and mitochondrial function.
• Target for therapeutic intervention in T cell exhaustion.
• Provides a mechanism for viral and bacterial evasion of host immunity.
What Happens During positive regulation of proteasomal protein catabolic process?
Substrate Recognition and Ubiquitination
In simple terms: Proteins that need to be destroyed are first tagged with a small molecule called ubiquitin.
The first step in positive regulation of proteasomal degradation is the recognition of target proteins by E3 ubiquitin ligases, which attach polyubiquitin chains to lysine residues on substrates. This tagging is highly specific and is often upregulated in response to cellular signals. For example, the ubiquitin ligase KLHL6 drives resistance to CD8+ T cell dysfunction by targeting specific substrates for degradation. Similarly, the FBXO5-DOK6 axis regulates proteasome-cytomechanics and contributes to temozolomide resistance in glioblastoma. The activity of these ligases can be positively regulated by post-translational modifications or by interaction with adaptor proteins.
Proteasome Activation and Assembly
In simple terms: The proteasome, a large protein complex, is activated or assembled to degrade tagged proteins.
Positive regulation can occur at the level of the proteasome itself, such as through increased expression of proteasome subunits or assembly of the 26S proteasome from the 20S core and 19S regulatory particles. Extracellular proteasomes can also be regulated and may function in the extracellular space. In fission yeast, proteasome regulation influences petite-negativity, a phenotype related to mitochondrial function. Activation of the proteasome can be mediated by factors that enhance its catalytic activity or by modulating its interaction with substrates.
Substrate Delivery and Deubiquitination
In simple terms: Tagged proteins are delivered to the proteasome, and sometimes the tag is removed before degradation.
Ubiquitinated substrates are recognized by shuttle factors and delivered to the proteasome. Deubiquitinating enzymes (DUBs) can remove ubiquitin chains, but positive regulation of degradation often involves DUBs that facilitate substrate unfolding or recycling of ubiquitin. The balance between ubiquitination and deubiquitination determines the fate of the substrate. For instance, circNDUFB2 destabilizes IGF2BPs via the proteasome, activating anti-tumor immunity. This step is tightly regulated to ensure efficient degradation.
Degradation and Downstream Effects
In simple terms: The tagged protein is chopped into small pieces, and this affects many cellular processes.
Once the substrate is inside the proteasome, it is degraded into short peptides. This process is ATP-dependent and occurs in the 20S core particle. The degradation of key regulatory proteins leads to downstream effects such as cell cycle progression, apoptosis, or immune activation. For example, proteasome-guided haem signalling contributes to T cell exhaustion, linking degradation to metabolic and immune regulation. Methionine metabolism can also influence proteasome activity in cisplatin-resistant bladder cancer. Thus, positive regulation of proteasomal degradation has broad consequences for cell physiology.
Key Genes Involved in GO:1901800 positive regulation of proteasomal protein catabolic process
The following genes and proteins are key players in the positive regulation of proteasomal protein catabolic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KLHL6 | E3 ubiquitin ligase that targets substrates for degradation | Drives resistance to CD8+ T cell dysfunction |
| FBXO5 | E3 ubiquitin ligase component of SCF complex | Regulates proteasome-cytomechanics and temozolomide resistance |
| DOK6 | Substrate adaptor for FBXO5 | Involved in glioblastoma chemoresistance |
| IGF2BP | RNA-binding protein destabilized by circNDUFB2 | Modulates anti-tumor immunity in NSCLC |
| circNDUFB2 | Circular RNA that promotes degradation of IGF2BPs | Inhibits non-small cell lung cancer progression |
| PSMA1 | 20S proteasome alpha subunit | Core component of proteasome |
| PSMB5 | 20S proteasome beta subunit with catalytic activity | Target of proteasome inhibitors |
| PSMC2 | 19S regulatory particle ATPase | Required for substrate unfolding and translocation |
| UCHL5 | Deubiquitinating enzyme associated with proteasome | Regulates substrate processing |
| USP14 | Proteasome-associated deubiquitinating enzyme | Modulates degradation efficiency |
| NEDD8 | Ubiquitin-like protein that modifies cullin-RING ligases | Activates E3 ligases for proteasomal degradation |
| CUL1 | Scaffold protein of SCF ubiquitin ligase complex | Facilitates substrate ubiquitination |
| RBX1 | RING-box protein in SCF complex | Essential for E3 ligase activity |
| SKP1 | Adaptor in SCF complex | Links substrate receptors to cullin |
| BAG6 | Chaperone-like protein involved in degradation of misfolded proteins | Facilitates proteasomal targeting |
| VCP/p97 | AAA-ATPase that extracts proteins from complexes for degradation | Regulates proteasomal degradation of membrane proteins |
How Is positive regulation of proteasomal protein catabolic process Regulated?
The positive regulation of proteasomal protein catabolic process is itself regulated at multiple levels. Upstream signalling pathways, such as mTOR and the integrated stress response (ISR), can influence proteasome activity and substrate availability. For example, mTOR inhibition can enhance proteasomal degradation of specific substrates, while ISR activation increases the expression of proteasome subunits. Additionally, post-translational modifications of proteasome components, such as phosphorylation and ubiquitination, can modulate their activity. The availability of ubiquitin and the activity of E3 ligases are also tightly controlled. In T cells, proteasome-guided haem signalling contributes to exhaustion, indicating metabolic regulation of this process. Methionine metabolism can alter the redox state and affect proteasome function in cancer cells. Thus, positive regulation is integrated with cellular metabolism and stress responses.
positive regulation of proteasomal protein catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FBXO5 | Glioblastoma chemoresistance | Knockout in glioblastoma cell lines, followed by temozolomide treatment |
| KLHL6 | T cell dysfunction and immunotherapy resistance | Overexpression in primary T cells or CAR-T models |
| circNDUFB2 | Non-small cell lung cancer | Overexpression in NSCLC cell lines and xenografts |
| Methionine metabolism genes | Cisplatin-resistant bladder cancer | Metabolic profiling and knockout in bladder cancer cells |
| VCP/p97 | Neurodegeneration | Knock-in of disease-associated mutations in neuronal cells |
Cancer
Dysregulation of proteasomal degradation is a hallmark of cancer. Overexpression of E3 ligases such as FBXO5 can lead to enhanced degradation of tumor suppressors, promoting chemoresistance in glioblastoma. In non-small cell lung cancer, circNDUFB2 destabilizes IGF2BPs, leading to activation of anti-tumor immunity. Methionine metabolism orchestrates proteasome activity in cisplatin-resistant bladder cancer, suggesting that targeting this pathway could overcome resistance. KLHL6-mediated degradation drives resistance to CD8+ T cell dysfunction, linking proteasome regulation to immunotherapy response.
Neurodegeneration
Impaired proteasomal degradation contributes to the accumulation of toxic protein aggregates in neurodegenerative diseases such as Alzheimer's and Parkinson's. Positive regulators of proteasomal activity are being explored as therapeutic targets to enhance clearance of misfolded proteins. For example, enhancing VCP/p97 activity or E3 ligase function could promote degradation of aggregation-prone proteins.
Immune Disorders and T Cell Exhaustion
Proteasome-guided haem signalling contributes to T cell exhaustion, a state of dysfunction in chronic infections and cancer. Positive regulation of proteasomal degradation can either promote or inhibit immune responses depending on the substrates targeted. KLHL6 drives resistance to CD8+ T cell dysfunction, suggesting that modulating its activity could enhance T cell function. Extracellular proteasomes may also play a role in immune modulation.
From positive regulation of proteasomal protein catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FBXO5 reduce proteasomal degradation and reverse chemoresistance? | CRISPR knockout of FBXO5 in glioblastoma cells |
| Can point mutation in KLHL6 alter substrate specificity? | CRISPR point mutation knock-in in T cells |
| Does overexpression of circNDUFB2 enhance IGF2BP degradation? | Overexpression vector in NSCLC cells |
| What is the role of proteasome subunit PSMB5 in drug resistance? | Knock-in of tagged PSMB5 for proteomics |
| Does methionine restriction affect proteasome activity? | Metabolic knockout models in bladder cancer |
| How does VCP/p97 mutation affect protein aggregation? | Knock-in of patient mutations in iPSC-derived neurons |
How to Study the positive regulation of proteasomal protein catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ubiquitinome proteomics | Global changes in ubiquitination | Identify substrates of E3 ligases |
| CRISPR knockout screen | Genes required for proteasomal degradation | Discover positive regulators |
| Degron reporter assay | Proteasome activity in live cells | Validate regulators and test inhibitors |
| Co-immunoprecipitation | Protein-protein interactions | Identify E3-substrate complexes |
| RNA-seq | Transcriptional changes | Assess downstream effects of degradation |
| Proteasome activity assay | Chymotrypsin-like, trypsin-like, caspase-like activities | Measure proteasome function |
| Immunofluorescence | Localization of proteasome and substrates | Study extracellular proteasome |
| Flow cytometry | Degradation of fluorescent substrates | Quantify proteasome activity in single cells |
Proteomics and Ubiquitinome Analysis
Mass spectrometry-based proteomics can quantify changes in protein abundance and ubiquitination sites upon modulation of positive regulators. For example, ubiquitinome analysis after KLHL6 overexpression can identify substrates. This method is essential for understanding the global impact of proteasomal degradation.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes that positively regulate proteasomal degradation. For instance, a screen for regulators of T cell exhaustion might identify KLHL6. Libraries targeting E3 ligases or proteasome subunits are particularly useful.
Reporter Assays
Fluorescent or luminescent reporters fused to degrons can measure proteasome activity in live cells. These assays are used to validate positive regulators identified in screens. They enable high-throughput screening of compounds or genetic perturbations.
Imaging and Localization Studies
Confocal microscopy and live-cell imaging can visualize proteasome localization and substrate degradation. Tagged proteasome subunits or substrates allow tracking of degradation dynamics. This is useful for studying extracellular proteasomes.
How CRISPR Can Be Used to Study GO:1901800 positive regulation of proteasomal protein catabolic process
Knockout
CRISPR knockout of positive regulators such as FBXO5 or KLHL6 can abolish proteasomal degradation of specific substrates, leading to substrate accumulation. This is used to study loss-of-function phenotypes in cancer and immune cells.
Point Mutation
Point mutations can be introduced into E3 ligases or proteasome subunits to disrupt catalytic activity or substrate recognition without affecting protein stability. For example, mutating the RING domain of KLHL6 can prevent ubiquitination.
Knock-in
Knock-in of tagged proteasome subunits (e.g., GFP-PSMB5) allows visualization and purification of proteasomes. This is useful for studying assembly and localization.
Overexpression
Overexpression of positive regulators like circNDUFB2 or FBXO5 can enhance proteasomal degradation and drive phenotypes such as chemoresistance or immune activation.
How EDITGENE Supports positive regulation of proteasomal protein catabolic process Research
Researchers studying positive regulation of proteasomal protein catabolic process-related genes often need to determine whether a candidate gene is causally involved in the regulation of proteasomal degradation. EDITGENE provides comprehensive CRISPR services to enable such investigations, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of proteasomal protein catabolic process research.
Frequently Asked Questions About positive regulation of proteasomal protein catabolic process
What is GO:1901800?
GO:1901800 is a Gene Ontology term for any process that activates or increases the frequency, rate or extent of proteasomal protein catabolic process.
What genes are involved in positive regulation of proteasomal protein catabolic process?
Key genes include KLHL6, FBXO5, DOK6, circNDUFB2, and proteasome subunits such as PSMB5.
How does positive regulation of proteasomal degradation affect cancer?
It can promote degradation of tumor suppressors or enhance immune evasion, contributing to chemoresistance and cancer progression.
What diseases are associated with dysregulated proteasomal degradation?
Cancer, neurodegeneration, and T cell exhaustion are linked to altered proteasomal regulation.
What experimental models are used to study this process?
CRISPR knockout, point mutation, knock-in, overexpression, and proteomics are common approaches.
How can I screen for regulators of proteasomal degradation?
Genome-wide CRISPR knockout or activation screens followed by proteasome activity assays can identify positive regulators.
What is the role of ubiquitin ligases in this process?
Ubiquitin ligases such as KLHL6 and FBXO5 tag substrates with ubiquitin, targeting them for proteasomal degradation.
Can proteasome activity be measured in live cells?
Yes, fluorescent degron reporters and activity assays allow real-time measurement of proteasome function.
What is the link between proteasome and T cell exhaustion?
Proteasome-guided haem signalling contributes to T cell exhaustion, and KLHL6 drives resistance to CD8+ T cell dysfunction.
How does methionine metabolism affect proteasomal degradation?
Methionine metabolism can alter redox state and proteasome activity, influencing cisplatin resistance in bladder cancer.
Conclusion
Positive regulation of proteasomal protein catabolic process (GO:1901800) is a central mechanism controlling protein turnover, with profound implications for cancer, immunity, and neurodegeneration. Understanding its regulators and mechanisms offers therapeutic opportunities. EDITGENE provides the necessary CRISPR tools to dissect this process and accelerate discovery.
References
- 1. Cheng H et al.. 2026. The ubiquitin ligase KLHL6 drives resistance to CD8(+) T cell dysfunction.. Nature 651(8105):451-461 PMID: 41535474
- 2. Li B et al.. 2021. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity.. Nat Commun 12(1):295 PMID: 33436560
- 3. Xu Y et al.. 2026. Proteasome-guided haem signalling axis contributes to T cell exhaustion.. Nature 653(8114):548-557 PMID: 41851457
- 4. Ben-Nissan G et al.. 2022. Biology of the Extracellular Proteasome.. Biomolecules 12(5) PMID: 35625547
- 5. Yang C et al.. 2023. Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment.. Cell Death Dis 14(8):525 PMID: 37582769
- 6. Amberg KL et al.. 2025. Proteasome regulation of petite-negativity in fission yeast.. BMC Biol 23(1):302 PMID: 41068765
- 7. Wang C et al.. 2025. Targeting the FBXO5-DOK6 axis to overcome temozolomide resistance in glioblastoma via proteasome-cytomechanics regulation.. Cancer Lett 634:218072 PMID: 41045986
- 8. Abbas R et al.. 2021. Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System.. Cells 10(12) PMID: 34943974
